<unk> agonists are useful in: * Suppression of spontaneous ovulation as part of controlled ovarian hyperstimulation, which is an essential component in in vitro fertilisation (IVF). Typically, after<unk> agonists have induced a state of hypoestrogenism, exogenous FSH is given to stimulate ovarian follicle, followed by human chorionic gonadotropins (hCG) to trigger oocyte release.<unk> agonists routinely used for this purpose are: buserelin, leuprorelin, nafarelin, and triptorelin. * Final maturation induction after having performed controlled ovarian hyperstimulation. Usage of<unk> agonist for this purpose necessitates using a<unk> antagonist instead of a<unk> agonist for suppression of spontaneous ovulation, because using<unk> agonist for that purpose as well inactivates the axis for which it is intended to work for final maturation induction. * Treatment of cancers that are<unk> lly sensitive and where a hypogonadal state decreases the chances of a recurrence. Thus they are commonly employed in the medical management of prostate cancer and have been used in patients with breast cancer. * Delaying puberty in individuals with precocious puberty. * Delaying puberty pending treatment decisions in children with gender dysphoria. * Management of female disorders that are dependent on estrogen production. Women with menorrhagia, endometriosis, adenomyosis, or uterine fibroids may receive<unk> agonists to suppress ovarian activity and induce a hypoestrogenic state. * Suppressing sex<unk>  levels in transgender people, especially transgender women. * Severe cases of hyperandrogenism, such as in congenital adrenal hyperplasia. * As part of the pharmacologic treatment of paraphilic disorders in sexual offenders or men with a high risk of sexual offending. Women of reproductive age who undergo cytotoxic chemotherapy have been pretreated with<unk> agonists to reduce the risk of oocyte loss during such therapy and preserve ovarian function. Further studies are necessary to prove that this approach is useful. Available forms s marketed for clinical or veterinary use Name Brand names Approved uses Routes Launch Azagly-nafarelin Gonazon Veterinary medicine (assisted reproduction; chemical castration) Implant; Injection 2005a 9,190 Buserelin Suprefact Breast cancer; Endometrial hyperplasia; Endometriosis; Female infertility (assisted reproduction); Prostate cancer; Uterine fibroids Nasal spray; Injection; Implant 1984 253,000 Deslorelin Ovuplant; Suprelorin Veterinary medicine (assisted reproduction; chemical castration) Implant; Injection 1994 85,100 Fertirelin Ovalyse Veterinary medicine (assisted reproduction) Injection 1981 41,000 Gonadorelin Factrel; Others Cryptorchidism; Delayed puberty; Diagnostic agent (pituitary disorders); Hypogonadotropic hypogonadism; Veterinary medicine (assisted reproduction) Injection; Infusion pump; Nasal spray 1978 259,000 Goserelin Zoladex Implant 1989 400,000 Histrelin Vantas; Supprelin LA Precocious puberty; Prostate cancer Implant 1993 283,000 Lecirelin Dalmarelin Veterinary medicine (assisted reproduction) Injection 2000a 19,700 Leuprorelin Lupron; Eligard; Procren Breast cancer; Endometriosis; Menorrhagia; Precocious puberty; Prostate cancer; Uterine fibroids Injection; Implant 1985 536,000 Nafarelin Synarel Precocious puberty; Endometriosis Nasal spray 1990 117,000 Peforelin Maprelin Veterinary medicine (assisted reproduction) Injection 2001a 3,240 Triptorelin Decapeptyl Breast cancer; Endometriosis; Female infertility (assisted reproduction); Paraphilias; Precocious puberty; Prostate cancer; Uterine fibroids Injection 1986 302,000 Notes: Hits = Google Search hits (as of February 2018). Footnotes: a = Launched by this year.<unk> agonists that have been marketed and are available for medical use include buserelin, gonadorelin, goserelin, histrelin, leuprorelin, nafarelin, and triptorelin.<unk> agonists that are used mostly or exclusively in veterinary medicine include deslorelin and fertirelin.<unk> agonists can be administered by injection, by implant, or intranasally as a nasal spray. Injectables have been formulated for daily, monthly, and quarterly use, and implants are available that can last from one month to a year. With the exception of gonadorelin, which is used as a progonadotropin, all approved<unk> agonists are used as antigonadotropins. The clinically used desensitizing<unk> agonists are available in the following pharmaceutical formulations: * Short-acting injection (once per day): buserelin, histrelin, leuprorelin, triptorelin * Long-acting depot injection or injected pellet (once every one to six months): leuprorelin, triptorelin * Injected implant (once every one to three months): buserelin, goserelin, leuprorelin * Surgically implanted pellet (once per year): histrelin, leuprorelin * Nasal spray (two to three times per day): buserelin, nafarelin
Gonadotropin-releasing hormone agonist
Gonadotropin-releasing hormone antagonist
Gonadotropin-releasing hormone modulator
Prolactin modulator
Antiandrogen
Thyroid blocker
17α-Alkylated anabolic steroid
Steroidal antiandrogen